Skip to main content

Table 4 Demographic data of patients with partial response and failure to predominant sodium channel blocking antiseizure medications

From: Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients

  All (n = 24) Partial response (n = 5) Failure (n = 19) p
Onset age 15.0 (6.0–19.5) 6.5 (1.3–14.0) 16.0 (10.0–21.0) 0.586
Male 10 (41.7) 2 (40.0) 8 (42.1) reference
Female 14 (58.3) 3 (60.0) 11 (57.9) 1.000
Seizure type
 Focal 17 (70.8) 2 (40.0) 15 (78.9) 0.224
 Generalized 5 (20.8) 2 (40.0) 3 (15.8)  
 Unspecified 2 (8.3) 1 (20.0) 1 (5.3)  
Etiology
 Structural 5 (20.8) 1 (20.0) 4 (21.1) 0.331
 CNS infection 1 (4.2) 1 (20.0) 0 (0.0)  
 Genetic 1 (4.2) 0 (0.0) 1 (5.3)  
 Autoimmune 2 (8.3) 0 (0.0) 2 (10.5)  
 Unknown 15 (62.5) 3 (60.0) 12 (63.2)  
Number of ASMs
 1 6 (25.0) 1 (20.0) 5 (26.3) 0.965
 2 10 (41.7) 2 (40.0) 8 (42.1)  
 3 7 (29.2) 2 (40.0) 5 (26.3)  
 4 0 (0.0) 0 (0.0) 0 (0.0)  
 5 1 (5.9) 0 (0.0) 1 (5.3)  
Concurrent ASMs
 Carbamazepine 8 2 6  
 Clobazam 1 0 1  
 Gabapentin 1 0 1  
 Lacosamide 2 1 1  
 Lamotrigine 10 1 9  
 Levetiracetam 14 3 11  
 Oxcarbazepine 4 2 2  
 Perampanel 1 0 1  
 Phenobarbital 1 0 1  
 Phenytoin 9 2 7  
 Vigabatrin 1 0 1  
  1. Continuous variables were presented as median (interquartile range)
  2. Categorical variables were presented as n (%)
  3. Abbreviations: CNS central nervous system, ASM antiseizure medication